Pharmacologic Reversal of Xylazine-Induced Unconsciousness in Rats.

Area of Science:

• Neuroscience
• Pharmacology
• Toxicology

Background:

• Xylazine, an alpha-2 adrenergic agonist used in veterinary medicine, is increasingly found as an adulterant in illicit drugs.
• Xylazine-related overdoses and fatalities are rising, necessitating effective reversal agents.
• Atipamezole, an alpha-2 antagonist, reverses xylazine in animals but is not approved for human use.

Purpose of the Study:

• To investigate alternative reversal agents for xylazine-induced unconsciousness.
• To compare the efficacy of atipamezole, d-amphetamine, chloro-APB, and atomoxetine in a rat model.
• To assess the impact of these agents on electroencephalogram (EEG) patterns and recognition memory.

Main Methods:

• Xylazine was administered intravenously to induce loss of righting reflex (LORR) in Sprague-Dawley rats.
• Potential reversal agents (atipamezole, d-amphetamine, chloro-APB, atomoxetine) were administered intravenously.
• Time to return of righting reflex (RORR), EEG activity, and novel object recognition memory were assessed.

Main Results:

• Atipamezole, d-amphetamine, and chloro-APB significantly reduced the time to RORR compared to saline controls.
• Atomoxetine did not significantly alter the time to RORR.
• EEG analysis revealed that atipamezole, d-amphetamine, and chloro-APB restored brain activity patterns similar to the awake state.
• No tested reversal agent restored recognition memory in the novel object recognition test.

Conclusions:

• Atipamezole, d-amphetamine, and chloro-APB are effective in accelerating emergence from xylazine-induced unconsciousness.
• These agents normalize EEG patterns associated with wakefulness.
• Current reversal agents do not restore xylazine-impaired recognition memory, indicating a need for further research.